FDA Highlights Importance Of Computational Modeling
This article was originally published in The Gray Sheet
Executive SummaryDuring the Oct. 14 panel meeting, Bram Zuckerman, director of FDA’s Division of Cardiovascular Devices, emphasized the importance of computational modeling to further understand complex vascular regions like femoral arteries.
You may also be interested in...
A collaboration between Novo and Fauna will look at animal hibernation and genetic sequencing for hints toward novel therapies for obesity. Pfizer will use Insilico’s machine learning technology in target validation.